Cargando…
Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors
Introduction: To address the issue of limited data on and inconsistent findings for genetic alterations in pancreatic neuroendocrine tumors (pNETs), we analyzed sequences of known pNET-associated genes for their impact on clinical outcomes in a Taiwanese cohort. Methods: Tissue samples from 40 patie...
Autores principales: | Chou, Wen-Chi, Lin, Po-Han, Yeh, Yi-Chen, Shyr, Yi-Ming, Fang, Wen-Liang, Wang, Shin-E, Liu, Chun-Yu, Chang, Peter Mu-Hsin, Chen, Ming-Han, Hung, Yi-Ping, Li, Chung-Pin, Chao, Yee, Chen, Ming-Huang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166493/ https://www.ncbi.nlm.nih.gov/pubmed/27994516 http://dx.doi.org/10.7150/ijbs.16233 |
Ejemplares similares
-
Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2014) -
Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors
por: Lin, Liang-Yu, et al.
Publicado: (2017) -
mTOR Inhibitors in Advanced Biliary Tract Cancers
por: Wu, Chao-En, et al.
Publicado: (2019) -
Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors
por: Chu, Pei-Yi, et al.
Publicado: (2017) -
mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021)